Trademark: 97679811
Word
THERADIGM
Status
Pending
Status Code
688
Status Date
Tuesday, December 5, 2023
Serial Number
97679811
Mark Type
4000
Filing Date
Wednesday, November 16, 2022
Published for Opposition
Tuesday, October 10, 2023

Trademark Owner History
Vesta Therapeutics, Inc. - Owner At Publication

Classifications
40 Biomanufacturing for others, namely, manufacturing of biologics, cells, scaffolds and matrices, and related biological materials using biological organisms in the manufacturing process
5 Biologics, namely, cells and cell lines for use as therapeutics to repair, replace or preserve cells and tissues, or to mobilize the immune system, including against pathogens or cancers, or to modulate the immune system, including against auto-immune disease or inflammatory conditions; Stem cells and progenitor cells for use as therapeutics to repair, replace or preserve cells and tissues, or to mobilize the immune system, including against pathogens or cancers, or to modulate the immune system, including against auto-immune disease or inflammatory conditions; Bone Marrow Stromal Cells (BMSCs) for use as therapeutics to repair, replace or preserve cells and tissues, or to mobilize the immune system, including against pathogens or cancers, or to modulate the immune system, including against auto-immune disease or inflammatory conditions; Adipose tissue stromal cells (ASCs) for use as therapeutics to repair, replace or preserve cells and tissues, or to mobilize the immune system, including against pathogens or cancers, or to modulate the immune system, including against auto-immune disease or inflammatory conditions; Growth factors for use as medicinal products, namely, cell growth media for growing cells for medical or clinical use; Proteins for use as medicinal products, namely, protein arrays for medical diagnosis purposes; Peptides for use as medicinal products, namely, synthetic peptides for the treatment of neuro-degenerative disorders, metabolic disorders, inflammatory and auto-immune disorders, orthopedic disorders, heart and vasculature disorders, and cancer; Clinical medical reagents, namely, small molecules for use as medicinal products; Clinical medical reagents, namely, telomerase activators (agonists) and inhibitors (antagonists) for use as medicinal products; Pharmaceutical preparations, namely, cell-based therapeutics for the treatment of Central Nervous System (CNS) disorders, demyelinating disorders, auto-immune disorders, peripheral neural disorders, and autism; Pharmaceutical preparations, namely, cell-based therapeutics for the treatment of stroke, spinal cord injury, brain injury, brain tumors, Amyotrophic Lateral Sclerosis (ALS) (Lou Gehrig's Disease), Parkinson's disease, Huntington's disease, peripheral neural disorders, autism, Multiple Sclerosis (MS), and MS-like diseases with cognitive dysfunction, mobility dysfunction, and neurological disorders; Pharmaceutical preparations for the treatment of the Central Nervous System (CNS), namely, stroke, spinal cord injury, brain injury, brain tumors, Amyotrophic Lateral Sclerosis (ALS) (Lou Gehrig's Disease), Parkinson's disease, Huntington's disease, Multiple Sclerosis (MS), and cognitive dysfunction, mobility dysfunction, and neurological disorders, peripheral neural disorders, and autism
1 Biologics, namely, cells and cell lines for scientific and research use in the development, testing and manufacture of therapeutics; Biologics, namely, cells and cell lines for scientific and research use in the production of biologic substances, including growth factors and proteins; Biologics, namely, cells and cell lines for scientific and research use for the testing of chemical substances; Cells and cell lines for scientific and research use, namely, stem cells and progenitor cells for use in the development, testing and manufacture of therapeutics; Cells and cell lines for scientific and research use, namely, stem cells and progenitor cells for use in the production of biologic substances, including growth factors and proteins; Cells and cell lines for scientific and research use, namely, stem cells and progenitor cells for the testing of chemical substances; Cells and cell lines for scientific and research use, namely, Bone Marrow Stromal Cells (BMSCs) for use in the development, testing and manufacture of therapeutics; Cells and cell lines for scientific and research use, namely, Bone Marrow Stromal Cells (BMSCs) for use in the production of biologic substances, including growth factors and proteins; Cells and cell lines for scientific and research use, namely, Bone Marrow Stromal Cells (BMSCs) for the testing of chemical substances; Cells and cell lines for scientific and research use, namely, adipose tissue stromal cells (ASCs) for use in the development, testing and manufacture of therapeutics; Cells and cell lines for scientific and research use, namely, adipose tissue stromal cells (ASCs) for use in the production of biologic substances, including growth factors and proteins; Cells and cell lines for scientific and research use, namely, adipose tissue stromal cells (ASCs) for the testing of chemical substances
44 Medical testing for diagnostic or treatment purposes; Medical treatment of neuro-degenerative disorders, metabolic disorders, inflammatory and auto-immune disorders, orthopedic disorders, and heart and vasculature disorders; Medical treatment of stem and progenitor cells and bone marrow stromal cells and adipose tissue stromal cells; Medical treatment of Central Nervous System (CNS) disorders; Medical treatment of stroke, spinal cord injury, brain injury, brain tumors, Amyotrophic Lateral Sclerosis (ALS) (Lou Gehrig's Disease), Parkinson's Disease, Huntington's Disease, Multiple Sclerosis (MS), and MS-like diseases, peripheral neural disorders, and autism; Medical treatment, namely, cell-based therapies for the treatment of neurological and Central Nervous System (CNS) injuries and disorders, demyelinating disorders, auto-immune disorders, peripheral neural disorders, and autism; Medical and pharmaceutical consultation in the field of stem and progenitor cells and bone marrow stromal cells and adipose tissue stromal cells; Medical and pharmaceutical consultation in the field of Central Nervous System (CNS) disorders; Medical and pharmaceutical consultation in the field of stroke, spinal cord injury, brain injury, brain tumors, Amyotrophic Lateral Sclerosis (ALS) (Lou Gehrig's Disease), Parkinson's Disease, Huntington's Disease, Multiple Sclerosis (MS), and MS-like diseases, peripheral neural disorders, and autism; Medical and pharmaceutical consultation in the field of cell-based therapies for the treatment of neurological and Central Nervous System (CNS) injuries and disorders, demyelinating disorders, auto-immune disorders, peripheral neural disorders, and autism
42 Pharmaceutical research and development services; Biological research and development services; Medical research and development services in the field of regenerative medicine and immunotherapies; Medical and pharmaceutical research in the field of stem and progenitor cells and bone marrow stromal cells and adipose tissue stromal cells

Trademark Events
Dec 5, 2023
Noa E-Mailed - Sou Required From Applicant
Oct 26, 2023
Assigned To Examiner
Oct 10, 2023
Official Gazette Publication Confirmation E-Mailed
Oct 10, 2023
Published For Opposition
Sep 20, 2023
Notification Of Notice Of Publication E-Mailed
Aug 31, 2023
Approved For Pub - Principal Register
Aug 29, 2023
Assigned To Examiner
Dec 7, 2022
New Application Office Supplied Data Entered
Nov 19, 2022
New Application Entered

Trademark Alertz updated from USPTO on 2030-01-24